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This study investigated for the first time brain ischemic involvement in 19 consecutive neurologically 
asymptomatic PNH patients by non-enhanced cerebral MRI, and by intracranial arterial and venous 
angio-MRI. Eleven cases (58%, 7 aged <65) showed pathological findings: 9 white matter (WM) 
abnormalities related to chronic ischemic small vessel disease, 2 a focal abnormality >5 mm, and 5 
cases a score >4 by the age-related white matter changes (ARWMC) scale. Compared with age and sex-
matched controls (1:2 ratio), patients showed an increased frequency of periventricular WM vascular 
degeneration (32% versus 5.2%, p = 0.04) and of severe lesions (ARWMC scale score >4) (26% versus 
2.6%, p = 0.05), and a higher overall ARWMC scale score (3.5 ± 1.07 versus 2.0 ± 0.8, mean ± SD, 
p < 0.0001). Notably, vascular abnormalities suspected for prior partial venous thrombosis, were 
observed in PNH cases only. MRI lesions were not related to blood counts, hemolytic markers, clone 
size, disease duration, and therapy with eculizumab. Neurological examination was unremarkable in 
all patients but one (Parkinson disease). Psychiatric assessment revealed a case of generalized anxiety 
disorder, 1 bipolar disorder type 2, and 1 adjustment disorder. In conclusion, brain MRI may be useful at 
diagnosis and during the course of the disease to explore subclinical neurological involvement.
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired stem cell disorder (incidence of 2–6 per million) 
characterized by hemolytic anemia, marrow failure and thrombosis. It is due to a mutation in the phosphatidylin-
ositol glycan class A (PIG-A) gene, which results in a deficiency of glycosylphosphatidyl-inositol (GPI)-anchored 
proteins, including complement regulatory CD55 and CD59. In particular, erythrocytes belonging to a PNH 
clone are abnormally sensitive to complement activation (exacerbated by surgery, infection, inflammation, or 
pregnancy), resulting in chronic intravascular hemolysis1. Venous thrombosis, particularly in abdominal and in 
intracranial veins, is the leading cause of mortality in patients with PNH, accounting for 40–67% of deaths with 
known causes2. Several mechanisms, including prothrombotic microparticles, proinflammatory cytokines and 
complement factors, activated platelets, and defective fibrinolysis have been hypothesized to play a role; how-
ever, the precise bases of this thrombophilic state, sometimes occurring in a thrombocytopenic patient, are still 
unknown. In addition, high plasma levels of free hemoglobin and subsequent depletion of nitric oxide (NO), a 
regulator of smooth muscle tone, may contribute to microvascular thrombosis, accounting for symptoms such 
as dysphagia, abdominal pain, headache, and erectile dysfunction1–4. Altogether, subclinical microthrombi and 
hemolysis-associated NO scavenging result in organ damage and death: PNH patients have an increased risk 
of chronic kidney disease and pulmonary hypertension and a reduced 10-year survival rate (50% for patients 
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diagnosed before 1970 and 75% in a more recent series)4–7. Today, eculizumab, a humanized monoclonal antibody 
that inhibits terminal complement activation, has dramatically changed the natural history of the disease, provid-
ing a 92% reduction in the risk of thromboembolism, along with an effective reduction of hemolysis and trans-
fusion requirements, and with improvements in pulmonary hypertension and renal function8–13. Thrombotic 
events in PNH generally occur in unusual sites, such as hepatic, portal, mesenteric, splenic, and renal veins. Brain 
involvement is anecdotic in the literature14–16. The largest series reported17 described 15 PNH cases with cerebral 
venous thrombosis, mostly women, and younger than a control population without PNH; 3 cases had a concom-
itant splancnic thrombosis and 1 patient died. Few cases (about 9) of ischemic strokes are reported, that were 
fatal in about 1/3 of cases18. More recently, in a PNH case with mild left hemiparesis, a brain computed tomog-
raphy scan showed multiple lacunar infarcts, and a magnetic resonance demonstrated several acute and chronic 
ischemic stroke areas19. Moreover, cerebral occlusive lesions involving various intracranial arteries have been 
reported in PNH as a result of Moya-Moya phenomenon20,21. However, no systematic studies have been reported 
in neurologically asymptomatic patients. The aim of this study was to investigate brain involvement in asymp-
tomatic PNH patients, either or not in eculizumab treatment, by non-enhanced cerebral magnetic resonance 
imaging (MRI), and by intracranial arterial and venous angio-MRI, and to compare MRI findings with an age 
and sex-matched control group. Neuro-radiological patients’ findings were completed with a neuro-psychiatric 
evaluation, and correlated with clinical/hematologic features and therapy.
Results
Clinical and hematological characteristics of patients. The main clinical and hematological param-
eters of patients are shown in Table 1. Seventeen out of 19 patients were classical hemolytic (63% transfusion 
dependent before treatment with eculizumab and 1 patient also after), and 2 PNH in the context of aplastic 
anaemia (all transfusion-dependent until treatment with ATG-CyA). The majority of patients were female (M:F 
ratio of 0.46), and median age at diagnosis was 44 years, with a wide range (17–80). Asthenia and dyspnea on 
exertion were present in all patients and abdominal pain in 42% (N. 1, 2, 4, 6, 11, 12, 15, and 16). Four cases (N. 
2, 6, 8 and 12) experienced a thrombotic event involving the sovrahepatic veins, the retinal arteria and the renal 
veins, respectively. Hemoglobin (Hb) values showed a great variability (median 9.6 g/dL, range 6.7–12.9) as well 
as LDH, with a median increase of 3.7-fold (range 1.2–16.3) over upper limit of normal (ULN). Seventy-three 
per cent of patients displayed a clone size greater than 50% GPI negative cells, and only 2 patients lower than 
20%. Thrombotic events were not correlated with clone size, as they occurred in 3 cases with a clone size >50% 
but also in a patient with a clone size <50%. However, patients who had a thrombotic event displayed greater 
Patient 
N.
Year of 
diagnosis PNH type
Data at diagnosis
Therapy with 
eculizumab, 
starting date
Data at last follow-up (2015/2016)
Age (yrs)/ 
gender
Hb  
(g/dL)
LDH (% 
ULN)
PMN 
(% GPI 
neg)
Reticulocytes 
(*103/mmc)
Age 
(yrs)
Hb  
(g/dL)
LDH (% 
ULN)
PMN  
(% GPI neg)
Reticulocytes 
(*103/mmc)
1 1996 hemolytic 48/F 12,0 9,5 48 126 yes, 2005 68 11,9 1,2 33 80
2 1997 hemolytic 31/F 8,2 4,3 63 251 yes, 2009 50 14,2 0,8 58 169
3 1997 hemolytic 31/M 11,4 na 87 92 yes, 2009 50 10,2 1,1 99 87
4 1999 hemolytic 24/F 9,9 1,5 33 83 no 41 8,6 6,7 80 158
5 2002 hemolytic 20/F 8,4 6,8 80 257 yes, 2008 34 8,4 0,9 97 208
6 2002 hemolytic 44/M 11,7 2,9 99 63 yes, 2005 58 6,9 2,3 93 249
7 2004 hemolytic 68/M 9,2 9,1 60 58 no 80 13,1 5,2 6 129
8 2005 hemolytic 43/F 6,7 5,4 42 65 no 54 11,1 2,2 76 63
9 2006 hemolytic 25/M 11,5 2,5 75 210 yes, 2007 35 12,7 1,6 77 248
10 2006 hemolytic 63/F 8,1 4,0 67 59 yes, 2009 73 9 1 99 237
11 2006 hemolytic 50/M 10,8 7,8 20 79 no 60 13,9 1 13 52
12 2007 hemolytic 46/F 8,7 16,3 90 133 yes, 2008 55 11,2 1 92 125
13 2007 aplastic 31/F 9,6 1,2 14 30 no 40 10,6 4,4 75 93
14 2007 aplastic 49/F 7,9 1,9 56 48 no 58 12,1 4,7 89 71
15 2011 hemolytic 31/M 10,5 8,6 81 123 yes, 2011 36 10,5 1 94 150
16 2013 hemolytic 17/F 9,8 3,4 69 153 yes, 2014 20 12,5 1,1 66 164
17 2014 hemolytic 50/F 10,9 2,6 64 73 no 52 11,1 4,9 74 145
18 2014 hemolytic 80/F 8,1 3,1 93 115 no 82 11,1 4,0 92 124
19 2016 hemolytic 55/F 9,6 1,8 50 72 no 56 12,6 1,4 nd 77
Table 1. Clinical and hematologic parameters of PNH patients. t > ULN: times over the upper limit of normal, 
nd: not done, na: not available. Median values at diagnosis: WBC were 3.68 × 103/mmc (range 1.7–7.04 × 103/
mmc); PMN 2.22 × 103/mmc (0.5–3.7 × 103/mmc); PLT 160 × 103/mmc (38–362 × 103/mmc); Median values at 
last follow up: WBC 3.91 × 103/mmc (2.6–5.04 × 103/mmc); PMN 2.24 × 103/mmc (1.16–2.76 × 103/mmc); PLT 
159 × 103/mmc (range 81–322 × 103/mmc); Normal ranges: WBC 4.8–10.8 × 103/mmc; PMN 1.50–6.50 × 103/
mmc; PLT 130–400 × 103/mmc; Hb male 13.5–17.5 g/dL, Hb female 12.0–16 g/dL; LDH 135–214 U/L; 
Reticulocytes 20–100 × 103/mmc.
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median LDH levels (7.2 ± 6.1 versus 4.6 ± 3.1 folds over ULN, mean ± SD), and median clone size (73.5 ± 26 
versus 59.8 ± 23% of GPI negative cells, mean ± SD) than cases without thrombosis. As regards abdominal pain, 
median LDH levels were greater in symptomatic cases (6.8 ± 4.8 versus 3.8 ± 2.5 folds over ULN, mean ± SD), 
while the clone size was comparable in subjects with or without symptoms.
Eculizumab was administered in 53% of cases because of transfusion dependence, abdominal pain and/or 
thrombosis. The median clone size was significantly higher in patients who underwent treatment (77.5 versus 
50%, p = 0.007); likewise, the former showed a more pronounced hemolytic pattern with an increased absolute 
reticulocyte count (median 147 × 103/mmc versus 72 × 103/mmc, p = 0.007), and LDH levels (4.3 over UNL ver-
sus 2.6 folds, not significant). At enrolment the median follow-up was 10 years (range 1–20); the median hemo-
globin values were increased compared to values at diagnosis, both because of treatment or transfusion support 
(in the eculizumab treated group from 9.2 to 11.2 g/dL and in the others from 9.6 to 11.1 g/dL). Median LDH 
significantly decreased in eculizumab treated cases (from 4.3 to 1 fold over ULN, p = 0.01), while it was increased 
(not significantly) in untreated cases (from 2.6 to 4.4 folds). Regarding the clone size, it increased from 64% to 
77% (not significantly), without a different behavior in treated or untreated cases. The clone size negatively corre-
lated with hemoglobin values (r = −0.7, p = 0.001) at the moment of the study. It is worth mentioning that subject 
N. 7, who had a classic transfusion-dependent hemolytic disease at diagnosis, showed a progressive amelioration 
overtime, with disappearance of transfusion need and remarkable reduction of GPI-negative granulocytes (from 
60% to 6%), normalization of hemoglobin values (from 9.2 to 13.1 g/dL), and decrease of hemolytic parameters 
(LDH form 9.1 to 5.2 folds over ULN) without any therapy. On the other hand, patient N. 6 suffered from a severe 
hemolytic PNH with persistence of transfusion dependence on eculizumab (1200 mg every ten days).
MRI findings. On MRI, 11/19 (58%) PNH patients showed pathological findings (Fig. 1). In particular, 9 
cases displayed WM abnormalities related to chronic ischemic small vessel disease, of whom 6 periventricular 
WM vascular degeneration, and 8 deep WM focal chronic ischemic lesions (5 cases have both sites involved). 
Moreover, a focal abnormality >5 mm was detected in 2 subjects (N. 7, N. 10), and the ARWMC scale for the 
evaluation of WM and basal ganglia lesions gave a score >4 in 5 subjects (N. 2, N. 6, N. 10, N. 11, N. 12). No 
Figure 1. Pathological brain MRI findings in PNH patients. (A) White Matter Changes (ARWMC scale, see 
Materials and Methods) (B). The T2 weighted axial image shows several t2 focal hyperintensities of WM due 
to chronic microinfarcts (patient N.10); (C) The FLAIR axial image shows periventricular hyperintensity due 
to vascular chronic degeneration (patient N. 7); (D) The Phase Contrast acquisition shows the asymmetry of 
venous sinuses with irregular walls of the right transverse sinus that can be due to a previously occurred venous 
thrombosis (patient N. 1). Control population (n = 38) findings: 9 leukoaraiosis, 19 deep WM focal chronic 
ischemic lesions (n = 5, score 1; n = 10, score 2; n = 3, score 3; n = 1, score 4); a lesion > 5mm was observed in 2 
subjects aged 53 and 83 years.
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subject displayed active or previous bleeding, nor were focal alterations of the basal nuclei by the ARWMC scale 
found. Two patients (80 and 81 yrs) showed atrophy of the cerebral hemispheres. Regarding vascular abnormal-
ities, one subject (N. 1) had hypoplastic left transverse sinus with irregularities in the sinus wall, suspected for 
prior partial venous thrombosis (Fig. 1). Three further cases (N. 6, N. 11, N. 16) displayed hypoplastic transverse 
sinus associated with collateral draining cortical veins, indistinguishable from anatomical variants. Intracranial 
artery stenosis or aneurysm, and Moya–Moya like alterations were not observed. Finally, cerebral MRI was unre-
markable in 8/19 subjects. Concerning the control group, 20/38 (52.6%) subjects showed at least one pathologic 
finding, in particular 2 periventricular WM vascular degeneration, and 19 deep WM focal chronic ischemic 
lesions (1 case have both sites involved). A focal abnormality >5 mm was detected in 2 subject aged 53 and 83 
years, and the ARWMC scale for the evaluation of WM and basal ganglia lesions gave a score >4 in 1 subject only 
(2.6%). Atrophy of the cerebral hemispheres was found in 1 subject aged 80 years. Of note, none of the controls 
showed vascular abnormalities, silent ischemic strokes, active or previous bleeding, or micro-hemorrhages. By 
comparing the two groups, the overall frequency of MRI alterations was not different between PNH and con-
trols (58% versus 52.6%). However, the number of subjects with periventricular WM vascular degeneration was 
greater in the patients (6/19, 32%, versus 2/38, 5.2%, p = 0.04), along with an increased frequency of severe lesions 
(ARWMC scale score >4 for WM and basal ganglia lesions) (5/19, 26% versus 1/38, 2.6%, p = 0.05). Consistently, 
the severity of deep WM focal chronic ischemic lesions was significantly greater in PNH cases compared with 
controls (ARWMC scale 3.5 ± 1.07 versus 2.0 ± 0.8, mean ± SD, p < 0.0001).
The clinical and hematological parameters of patients with or without any MRI abnormality (WM and vas-
cular alterations) are shown in Table 2. Mean age was significantly higher in the former, whereas blood counts, 
hemolytic markers and clone size showed no remarkable differences, except for hemoglobin values at enrol-
ment, which were higher in cases with MRI alterations. To note, hemoglobin values at diagnosis were slightly 
lower and LDH greater in subjects who displayed MRI abnormalities at enrolment, and individual hemoglobin 
levels negatively correlated with the ARWMC score (r = −0.45, p < 0.05). No relationship was found between 
history of abdominal pain/thrombosis and MRI pathological findings. Likewise, MRI abnormalities were not 
correlated with disease duration. As regards therapy with eculizumab, a pathological MRI was found in 6/10 sub-
jects under treatment and in 5/9 without; the sole significant vascular alteration was detected in a patient (N. 1) 
under treatment.
Neurological and psychiatric findings. Previous history of neurological disorders was observed in 4 
patients, whereas 15 had reported no events. Patient N. 10 experienced typical transient global amnesia in his 
early sixties, and N. 17 seizures at five years; both these events occurred before the diagnosis of PNH. Patient N.13 
complained headache since she was diagnosed with PNH. Patient N. 6 complained of progressive rest tremor 
in his left arm and leg twelve years after PNH diagnosis; he was diagnosed with possible Parkinson disease and 
started on specific treatment. Except for this subject displaying hypomimia, mild bradykinesia and rest tremor, 
neurological examination was unremarkable in all patients. Interestingly, patient 6 and 10 displayed significant 
WM MRI alterations (Fig. 1).
Eighteen subjects agreed to undergo to psychiatric assessment. Three patients resulted to have a psychiatric 
disorder according to SCID-I: 1 suffered from generalized anxiety disorder (GAD) (N. 4), 1 from bipolar disorder 
type 2 (N. 12) and 1 from adjustment disorder as a consequence of PNH diagnosis (N. 2). No patient manifested 
acute psychopathology at the time of assessment; however, 4 patients (N. 2, N. 4, N. 9 and N. 12) displayed mild 
psychiatric symptoms according to BPRS (Table 3). Only one patient (N. 7) showed a deficit of attentional and 
executive functions, and visual-motor coordination at TMT (prevalently in part B). As regards perception of 
healthy state (SF-36), 2 patients complained of remarkable limitation of work and other daily activities (RP), 
together with an increased perception of bodily pain (BP), and half of the patients declared an impairment of 
the normal social activities (SF). Surprisingly, all patients declared physical and mental well-being (no patho-
logical findings at PF and MH) in spite of the limits imposed by their physical condition; consistently, Hb values 
were negatively correlated with the physical functioning scores (PF) (r = −0.43, p < 0.05), i.e. the more anaemic 
patients declare a fitting bodily performance. Finally, the emotional-affective well being scores (MH) negatively 
MRI Abnormalities
Yes (n = 11) No (n = 8) Yes (n = 11) No (n = 8)
Data at diagnosis Data at last follow-up
Age (yrs) 50 ± 17* 32 ± 10 60 ± 17* 43 ± 8
Hb (g/dL) 9.5 ± 1.5 9.9 ± 1.6 12.2 ± 1.5* 10.4 ± 1.4
LDH (t > ULN) 5.8 ± 4.4 4.1 ± 2.9 2.1 ± 1.8 2.9 ± 2.2
Reticulocyte counts (x103/mmc) 105 ± 60 130 ± 69 134 ± 66 148 ± 60
GPI neg PMN cells (%) 65 ± 23 60 ± 27 63 ± 34 84 ± 11
WBC (μL) 3928 ± 1260 4490 ± 1709 3702 ± 1060 3676 ± 583
PMN cells (μL) 2045 ± 961 2239 ± 885 1931 ± 655 2096 ± 471
Plt (μL) 178091 ± 86290 131875 ± 101035 165564 ± 82344 162000 ± 65937
Table 2. Clinical and hematological parameters of patients with or without MRI abnormalities. Values are 
expressed as mean ± SD; *denotes p < 0.05, MRI abnormalities versus no MRI abnormalities.
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correlated with the disease duration (r = −0.51, p < 0.05), suggesting a progressive insight of the disease. No rela-
tionship was observed between MRI findings and neuro-psychiatric assessment.
Discussion
This is the first systematic evaluation of brain MRI findings and neuro-psychiatric status in neurologically asymp-
tomatic PNH patients. Pathological MRI findings, involving the periventricular and deep WM as well as the 
vascular district, were observed in more than a half of patients, this overall frequency being not significantly 
different from that observed in age- and gender-matched controls. However, the frequency of severe WM lesions 
(both periventricular and deep) was greater in PNH, and the overall degree of ischemic lesions was significantly 
greater in PNH cases compared with controls. Moreover, vascular abnormalities suspected for prior partial 
venous thrombosis, were observed in PNH cases only. Finally, a patient showed MRI findings suggestive of prior 
partial thrombosis of the transverse venous sinus, consistently with the observation that the transverse sinus was 
the second most frequent site of cerebral venous thrombosis in PNH patients with stroke17.
Our results showed no definite relationship between MRI pathological findings and history of previous 
thrombosis/abdominal pain, nor with known parameters that identify the clinical severity of PNH, in particular 
the clone size and LDH. It is known that overt thrombotic events occur more frequently in patients with large 
clone sizes, however, they are also observed in cases with small PNH clones22. It is worth considering that our 
PNH population is mostly composed by hemolytic patients, where thrombotic complications may be more fre-
quent. However, MRI results underline that ischemic and vascular abnormalities may be observed even in less 
severe cases, with smaller clones and normal hemoglobin values. Regarding therapy, of the 10 patients on eculi-
zumab, 7 had some ischemic/vascular involvement, likely reflecting more severe and long-lasting disease. Since 
the study has a retrospective design and no MRI findings are available before the start of therapy, no speculations 
can be done on the protective effect of eculizumab on the development or worsening of vascular injury. However, 
it is worth mentioning that a severe focal abnormality (with a diameter greater than 5 mm) was observed in a 60 
year-old man with no other known risk factors (hypertension, obesity, smoke) never treated with eculizumab. 
Interestingly, reduced small bowel blood flow by abdominal MRI has been useful in the decision to start therapy 
with eculizumab in patient N. 1623.
Little is known about the natural history of WM changes in the general population, starting from their devel-
opment to possible subsequent progression, due to the fact that MRI imaging is expensive and impractical for 
large scale population based studies. In 396 patients with acute stroke followed up to 12 years, ARWMC seems 
to be a significant predictor of poor long term survival and death by ischemic stroke24. Moreover, in a large 
non-institutionalized cohort of subjects aged >65 years without a history of stroke and followed-up for more 
than 10 years, ARWMCs predicted total cardiovascular and non-cardiovascular mortality25. MRI is considered 
the gold standard to identify both ischemic and vascular lesions of central nervous system and it is increasingly 
used in hemolytic disorders with known ischemic involvement, such as sickle cell disease (SCD), thrombotic 
microangiopathies and vasculitis26–29. In SCD up to 40% of cases were found to display silent cerebral infarction 
by MRI and these changes are related to cognitive impairment in adults26,30 and seem to start early in the course 
of the disease31. More recently, by resting state functional MRI, a selective disruption of connectivity among rel-
evant regions of the brain was observed in SCD, potentially leading to reduced cognition and altered functional 
brain dynamics32. In our cases, no significant cognitive impairment was found despite MRI alterations. Neither 
significant psychiatric symptoms nor a perception of poor health were found, although PNH subjects had insight 
Patient N. BPRS TMT-A TMT-B SF-36- PF SF-36- RP SF-36- BP SF-36- GH SF-36- VT SF-36- SF SF-36- MH
1 — — — — — yes — — — —
2 Yes/mild — — — — — — — — —
4 Yes/mild — — — — yes — — yes —
7 — yes yes — yes yes — — — —
8 — — — — — — — — yes —
9 Yes/mild — — — — — — — yes —
10 — — — — — — — — yes —
11 — — — — — — yes — yes —
12 Yes/mild — — — — — — — — —
13 — — — — — — — — yes —
14 — — — — — — yes — — —
15 — — — — — — — — yes —
17 — — — — — — — — yes —
18 — — — — yes yes — — yes —
19 — — — — — — — yes — —
Table 3. Pathological findings at psychiatric assessment. BPRS: Brief Psychiatry Rating Scale; TMT: Trail 
making test; SF-36: Short Form Health Survey; PF: Physical functioning; RP: Role-physical; BP: Bodily Pain; 
GH: General Health; VT: Vitality; SF: Social Functioning; MH: Mental Health. Yes indicates pathological 
findings. Patient N. 6 refused psychiatric assessment. Patient N. 3, N. 5, N. 16 displayed no pathological findings 
(not shown).
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about limitations in social functioning. Paradoxically, patients with more severe forms of illness (e. g, with lower 
hemoglobin values) reported higher levels of physical activities. One explanation, in absence of acute psychiatric 
disorders, might be that patients can benefit of a specialized care, and this may affect patients’ mood and related 
energies. Whether these observations are characteristic of PNH or are related to a chronic disease is difficult to 
define and may deserve further investigation.
In conclusion, brain MRI was able to reveal chronic ischemic and vascular lesions in a significant proportion 
of neurologically asymptomatic PNH patients, similarly to what reported in SCD, suggesting that these hemolytic 
conditions may share a common thrombophlic diathesis. As for abdominal MRI, brain evaluation may add fur-
ther information on the severity of a specific PNH patient, and be useful in the decision to start therapy, which is 
not always easy on the clinical/hematological basis. Although WM changes are largely related to age, our findings 
suggest being aware of possible asymptomatic vaso-occlusive events in PNH, leading to chronic small vessel dis-
ease in the brain, even in absence of neurological symptoms. This is of particular importance for younger patients, 
although only an ad hoc follow-up with MRI at diagnosis and at 2–3 years intervals will disclose whether or not 
these lesions would progress, remain stable, or regress, or may be influenced by therapy with eculizumab.
Patients and Methods
Patients. 19 consecutive patients diagnosed with PNH since 1996 till 2015 and followed at our Institution 
were enrolled from June 2015 until May 2016. The study was approved by the Ethical Committee of Human 
Experimentation of Area 2 Milano. All patients gave informed consent and the study has been conducted in 
accordance with the Declaration of Helsinki and with the EU ICH GCP Guidelines. Clinical and hematologic 
parameters at diagnosis, at enrolment and along the follow up were evaluated. PNH was diagnosed by cytometric 
analysis of CD55 and CD59 deficient granulocytes, monocytes, and erythrocytes by the fluorescent aerolysin 
(FLAER) method, and classified in the known categories: classical hemolytic, PNH in the context of other pri-
mary bone marrow disorders, such as aplastic anemia or myelodysplastic syndrome, and subclinical PNH, in 
which patients have small PNH clones but no clinical or laboratory evidence of hemolysis or thrombosis5. None 
of the subjects studied had previous history of stroke, head trauma, neurosurgery, and overt neurological disease, 
or reported known hereditary or acquired thrombophilic states.
MRI evaluation. All patients underwent non-enhanced cerebral magnetic resonance imaging (MRI), and 
intracranial arterial and venous MR-angiography (MRA). Brain MRI scans were obtained using a 3.0-T scan-
ner (Achieva, Philips Medical Systems). As controls we evaluated 38 consecutive age and sex-matched subjects 
(median age 44.5 years, range 23–87, 22 female and 16 male) who underwent MRI for reasons unrelated to 
ischemic symptoms (i.e. otalgia, ocular pain or sella turcica study), and showed no major pathological findings. 
Moreover, none of the controls had prior diagnosis of venous or arterial cerebral thrombosis, previous history of 
head trauma or neurosurgery. The following sequences were acquired from all subjects: (1) T2-weighted turbo 
spin echo (TSE) (repetition time [TR] 2491 ms; echo time [TE] 77 ms; flip angle 90°; 4-mm-thick axial slices; 
matrix size 505 × 512; field of view [FOV] 230 × 230 mm2); (2) fluid-attenuated inversion recovery (FLAIR) (TR 
11.000 ms; TE 125 ms; flip angle 90°; 4-mm-thick axial slices; matrix size 249 × 344; FOV 230 × 230 mm2); (3) 
3D T1- weighted fast field echo (TR 9.8 ms, TE 4.6 ms, flip angle 8°, FOV 240 × 240 mm2, matrix 240 × 240, slice 
thickness 1 mm, 220 contiguous sagittal slices); and (4) T2-weighted fast field echo (FFE) (TR 839 ms; TE 16 ms; 
FA 18°; 4-mm-thick axial slices; matrix size 205 × 256; FOV 230 × 230 mm2); (5) diffusion Echo Planar (TR 3367 
ms; TE 52 ms; FA 90°; 4 mm-thick-axial slice; matrix size 124 × 124; FOV 250 × 250 mm2; b-values 0–1000 s/
mm2); (6) 3D Time of Flight MRA (TR 25 ms; TE 3,4 ms; FA 20°; 1-mm-thick-contiguous axial size; matrix size 
407 × 800; 200 × 200mm2); (7) Phase Contrast MRA (TR 17 ms; TE 6 ms; FA 10°; 1.6-mm-thick- contiguous axial 
slices; matrix size 195 × 256; FOV 230 × 230 ms; velocity encoding 15 cm/s.
The following variables were evaluated by two blinded independent observers: a) chronic ischemic small ves-
sel disease defined as WM abnormalities with T2 and FLAIR hyperintense signal and quantified according to age 
related white matter changes (ARWMC) scale33 with distinction between deep white matter (WM) and basal gan-
glia (deep grey matter); b) diffuse T2 and FLAIR signal hyperintensity of the periventricular WM, consistent with 
chronic vascular degeneration or leukoaraiosis; c) focal alterations consistent with old silent ischemic strokes, 
defined as a malacic fluid-filled cavity (signal similar to cerebrospinal fluid, CSF) presenting with hyperintense 
signal on T2-weighted images and hypointense signal on FLAIR images without a history or physical findings of 
a focal neurological deficit34; d) active or previous bleeding or micro-hemorrhages; e) atrophy. Moreover, abnor-
malities of the circle of Willis and its branches (stenosis of intracranial arteries, aneurysms, Moya–Moya like 
alterations), and of cerebral venous sinus were evaluated. For WM lesions, the following scores were calculated: 
0 = no lesions, 1 = focal lesion, 2 = initial confluence of the lesions, 3 = broad involvement of the entire region 
with or without involvement of the U fibers. Likewise, for basal ganglia, 0 was used in case of no lesions, 1 for 
one focal lesion, 2 for more than one focal lesion, and 3 for confluent lesions. Scores were calculated separately 
for periventricular and deep WM, and evaluated separately for each side in the frontal, parietal-occipital and 
temporal lobes, in the infratentorial compartment, and in the basal ganglia. Furthermore, a more global score for 
leukoaraiosis was attributed 0 = absent, 1 = mild to moderate, and 2 = severe.
Neuro-psychiatric evaluation. Psychiatric evaluation included the following scales: the brief psychiatric 
rating scale (BPRS), the structured clinical interview for axis I DSM-IV-TR disorders (SCID-1)35,36, the short 
form (SF-36) health survey, and the trail making test (TMT). BPRS was used to measure general psychopathology, 
and total scores higher than 31 were considered pathological according to previous literature37. SF-36 was aimed 
to assess patients’ disability in seven different areas (physical activity, physical health, pain, general health, vital-
ity, social functioning, mental health); pathological findings were defined according to a large Italian sample38. 
TMT (part A and B) was used to assess patients’ cognitive functioning and specifically attention and executive 
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functioning; a time of execution >78 seconds for TMT-A and >273 seconds for TMT-B were considered as 
abnormal39. Of note, SF-36 has already been used to assess disability of hematological patients40. Psychiatric eval-
uations were performed by the same trained rater. A complete clinical neurologic assessment was also performed.
Statistical analysis. Descriptive analyses were performed on the total sample. Chi-square tests were used to 
compare qualitative variables, while Student’s t tests to compare continuous ones. Finally, Pearson’s linear corre-
lations were performed to relate clinical features of the total sample.
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